Outlook Therapeutics
Outlook Therapeutics reported revenue of $1 million in fiscal 2025. Its operating margin was −4,744.2%. The diluted share count rose 87.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Outlook Therapeutics lost money in fiscal 2025: a net loss of $62 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 14 | 17 | 23 | 15 | 8 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −1,118.7x | −40.5x | −21.0x | −22.7x | — |
| Current ratio | 3.2x | 1.4x | 0.7x | 0.6x | 0.4x |
| Quick ratio | 3.2x | 1.4x | 0.7x | 0.6x | 0.3x |
Cash flow
Projections
Project Outlook Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 6 insiders bought $7.9 million of Outlook Therapeutics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Ghiath M. SukhtianDirector, 10% owner | Bought | 2,525,252 | $0.99 | $2.5 million | Form 4 |
| Jul 29, 2026 | Faisal Ghiath SukhtianDirector | Bought | 95,398 | $1.05 | $100,168 | Form 4 |
| Jun 2, 2026 | Yezan Munther HaddadinDirector | Bought | 29,000 | $0.83 | $24,070 | Form 4 |
| May 28, 2026 | GMS Ventures & InvestmentsDirector, 10% owner | Bought | 8,539,709 | $0.59 | $5.0 million | Form 4 |
| May 27, 2026 | Faisal Ghiath SukhtianDirector | Bought | 122,174 | $0.41 | $50,091 | Form 4 |
| May 26, 2026 | Kurt J HilzingerDirector | Bought | 400,000 | $0.44 | $176,000 | Form 4 |
| May 26, 2026 | Yezan Munther HaddadinDirector | Bought | 34,000 | $0.44 | $14,960 | Form 4 |
| May 26, 2026 | Randy H ThurmanDirector | Bought | 5,000 | $0.43 | $2,150 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | −61.80 | −82.36 | −141.20 |
| Accruals ratio | −52.6% | −21.5% | −44.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — | — | — |
Compare
Put Outlook Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Outlook Therapeutics | FY25 | — | −4,744.2% | — | — | — | — | |
| Z Squared | FY25 | — | −956.9% | — | — | — | — | Compare |
| Celldex Therapeutics | FY25 | −78.0% | −18,599.8% | −13,829.1% | — | — | — | Compare |
| Inhibrx Biosciences | FY25 | 550.0% | −10,386.5% | −9,986.5% | — | — | 2 | Compare |
| Longeveron | FY25 | −49.9% | −1,942.2% | −1,575.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 3 | 4 | 3 | 8 | — | — | — | — | — | 1 |
| Revenue growth | −42.9% | 27.9% | −19.0% | 163.8% | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | 0 |
| Research and development | 33 | 24 | 18 | 24 | 26 | 39 | 42 | 26 | 42 | 27 |
| Operating income | −51 | −36 | −30 | −36 | −37 | −52 | −63 | −53 | −72 | −67 |
| Net income | −53 | −39 | −30 | −34 | −35 | −53 | −66 | −59 | −75 | −62 |
| Diluted EPS (US$) | −587.20 | −288.00 | −195.20 | −39.60 | −13.40 | −7.00 | −6.20 | −4.72 | −4.06 | −1.79 |
| Diluted shares (millions) | 0 | 0 | 0 | 1 | 4 | 8 | 11 | 12 | 18 | 35 |
| Cash flow | ||||||||||
| Cash from operations | −46 | −16 | −33 | −32 | −32 | −54 | −57 | −43 | −69 | −52 |
| Capital expenditure | 1 | 0 | 3 | 0 | — | — | — | — | — | — |
| Free cash flow | −47 | −16 | −36 | −33 | — | — | — | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 12 | 9 | 2 | 1 | 3 | 5 | 8 | 6 | 5 | 9 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 2 | 3 | 2 | 8 | 12 | 14 | 17 | 23 | 15 | 8 |
| Debt incl. finance leases | 3 | 0 | 0 | 5 | — | — | — | — | — | — |
| Total assets | 25 | 21 | 22 | 17 | 20 | 23 | 28 | 32 | 29 | 19 |
| Total liabilities | 31 | 52 | 43 | 28 | 17 | 18 | 20 | 47 | 102 | 51 |
| Shareholders' equity | −5 | −34 | −26 | −16 | 3 | 5 | 9 | −14 | −73 | −32 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | 4.0% |
| Operating margin | −1,723.3% | −941.4% | −960.1% | −445.6% | — | — | — | — | — | −4,744.2% |
| Net margin | −1,788.9% | −1,019.3% | −974.6% | −423.8% | — | — | — | — | — | −4,416.2% |
| Free cash flow margin | −1,563.3% | −414.5% | −1,160.2% | −401.8% | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | −1,606.2% | −386.5% | −1,179.2% | −237.9% | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | — | — | — | −1,430.3% | −990.0% | — | — | — |
| Return on assets | −176.4% | −168.4% | −139.9% | −175.2% | −191.2% | −249.9% | −257.3% | −193.9% | −246.6% | −263.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |